Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (341-350 of 483) with videos related to

Pageof 49
Sort By:
The Lancet. Oncology|November 22, 2012
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialJaafar Bennouna, Javier Sastre, Dirk Arnold, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
British Journal of Haematology|July 9, 2015
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-upHeinz Ludwig, Richard Greil, Tamas Masszi, et al.
The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
The Lancet. Oncology|June 7, 2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialMichael Gnant, Brigitte Mlineritsch, Herbert Stoeger, et al.
Leukemia Research|February 14, 2014
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survivalLisa Pleyer, Ulrich Germing, Wolfgang R Sperr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2012
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Matthew P Goetz, Vera J Suman, Tanya L Hoskin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort StudyGrzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 20, 2023
Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patientsNadège Néant, Guillaume Lingas, Alexandre Gaymard, et al.
Pageof 49

Showing results (341-350 of 483) with videos related to

Sort By:
Pageof 49
The Lancet. Oncology|November 22, 2012
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialJaafar Bennouna, Javier Sastre, Dirk Arnold, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
British Journal of Haematology|July 9, 2015
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-upHeinz Ludwig, Richard Greil, Tamas Masszi, et al.
The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
The Lancet. Oncology|June 7, 2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialMichael Gnant, Brigitte Mlineritsch, Herbert Stoeger, et al.
Leukemia Research|February 14, 2014
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survivalLisa Pleyer, Ulrich Germing, Wolfgang R Sperr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2012
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Matthew P Goetz, Vera J Suman, Tanya L Hoskin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort StudyGrzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 20, 2023
Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patientsNadège Néant, Guillaume Lingas, Alexandre Gaymard, et al.
Pageof 49